Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Aytu Biopharma (AYTU) Accumulated Depreciation & Amortization (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Accumulated Depreciation & Amortization for 14 consecutive years, with $735000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization fell 60.59% to $735000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $735000.0, a 60.59% decrease, with the full-year FY2025 number at $714000.0, down 66.4% from a year prior.
  • Accumulated Depreciation & Amortization was $735000.0 for Q3 2025 at Aytu Biopharma, up from $714000.0 in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $9.4 million in Q2 2022 to a low of -$3.8 million in Q3 2021.
  • A 5-year average of $2.0 million and a median of $1.9 million in 2024 define the central range for Accumulated Depreciation & Amortization.
  • Biggest YoY gain for Accumulated Depreciation & Amortization was 912.0% in 2021; the steepest drop was 11718.18% in 2021.
  • Aytu Biopharma's Accumulated Depreciation & Amortization stood at -$3.3 million in 2021, then skyrocketed by 192.99% to $3.1 million in 2022, then rose by 0.46% to $3.1 million in 2023, then tumbled by 78.85% to $651000.0 in 2024, then grew by 12.9% to $735000.0 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Accumulated Depreciation & Amortization are $735000.0 (Q3 2025), $714000.0 (Q2 2025), and $690000.0 (Q1 2025).